EUVIMEDEUVIMED entdecken
Crossref

Zonal‐Specific Risk Stratification Integrating Magnetic Resonance Imaging and Prostate‐Specific Antigen Density for Optimizing Prostate Biopsy Selection in Prostate‐Specific Antigen 4–20 ng/mL Patients

Liqin Yang, Ximing Wang, Zhiping Li, Fawei Huang, Yongsheng Zhang, Feng Cui, Pengfei Jin iD

The Prostate · 2026

DOI: 10.1002/pros.70075 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Prostate, 2026. Verfasst von Liqin Yang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Hangzhou Traditional Chinese Medicine Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, China. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Prostate-Specific Antigen, Magnetic Resonance Imaging, Prostate. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: The authors received no specific funding for this work..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To explore the stratification differences of MRI and prostate‐specific antigen (PSA) density (PSAD) in the peripheral zone (PZ) and transition zone (TZ) lesions, in order to optimize the biopsy decision for patients with PSA 4–20 ng/mL.

Methods

This retrospective study analyzed 1524 patients undergoing MRI and biopsy. Lesions were grouped by PZ and TZ and the differences of PSAD within the subgroups were explored. A zonal‐specific risk matrix was constructed by integrating the Prostate Imaging Reporting and Data System (PI‐RADS) categories and PSAD in overall, PZ, and TZ cohorts. Low or high‐threshold pathway was constructed by 10% or 30% clinically significant prostate cancer (csPCa) probability for PZ and TZ. Six biopsy pathways were then formed and evaluated by the biopsy avoidance, csPCa detection, and positive predictive value (PPV). Finally, decision curve analysis (DCA) was employed to evaluate the net benefit associated with each pathway.

Results

PZ lesions exhibited higher PSAD than TZ counterparts in equivalent PI‐RADS categories ( p < 0.05). In the risk matrix, for PI‐RADS 1–2 lesions, TZ required PSAD ≥ 0.15 ng/mL/cm 3 while PZ ≥ 0.20 ng/mL/cm 3 to achieve > 10% csPCa risk. For PI‐RADS 3 lesions, thresholds were ≥ 0.15 ng/mL/cm 3 (TZ) and ≥ 0.20 ng/mL/cm 3 (PZ) to trigger biopsy at > 30% csPCa risk. Among six pathways, the “PZ high + TZ high” pathway (PSAD ≥ 0.20 ng/mL/cm 3 for PZ and ≥ 0.15 ng/mL/cm 3 for TZ in PI‐RADS 3) achieved optimal balance, detecting 86.6% of csPCa while avoiding 48.0% of unnecessary biopsies, with a PPV of 69.1% (F1‐score = 0.77). DCA confirmed superior net clinical benefit for this pathway at ≥ 20% risk thresholds.

Conclusion

In the risk stratification of MRI and PSAD, considering zonal specific of the lesion is helpful to improve biopsy decisions in patients with PSA 4–20 ng/mL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsProstate-Specific AntigenMagnetic Resonance ImagingProstateHumansMaleRetrospective StudiesMiddle AgedAgedRisk AssessmentBiopsyImage-Guided Biopsy

Stichwörter der Autor:innen

Prostate Imaging Reporting and Data Systembiopsy optimizationprostate cancerprostate‐specific antigen densityrisk stratification

Substanzen

Prostate-Specific Antigen

Autor:innen und Institutionen

  • Department of Radiology, Hangzhou Traditional Chinese Medicine Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, China.
  • Department of Radiology, The First Affiliated Hospital of Soochow University, Suzhou, China.
  • Department of Radiology, Pinghu Hospital of Traditional Chinese Medicine, Pinghu, China.
  • Department of Radiology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.

ORCID-Profile: Pengfei Jin

Förderung

  • The authors received no specific funding for this work.

Zitieren

APA

Yang, L., Wang, X., Li, Z., Huang, F., Zhang, Y., Cui, F., & Jin, P. (2026). Zonal‐Specific Risk Stratification Integrating Magnetic Resonance Imaging and Prostate‐Specific Antigen Density for Optimizing Prostate Biopsy Selection in Prostate‐Specific Antigen 4–20 ng/mL Patients. The Prostate. https://doi.org/10.1002/pros.70075

Vancouver

Yang L, Wang X, Li Z, Huang F, Zhang Y, Cui F, et al. Zonal‐Specific Risk Stratification Integrating Magnetic Resonance Imaging and Prostate‐Specific Antigen Density for Optimizing Prostate Biopsy Selection in Prostate‐Specific Antigen 4–20 ng/mL Patients. The Prostate. 2026. doi:10.1002/pros.70075

BibTeX
@article{Yang2026,
  author = {Yang, Liqin and Wang, Ximing and Li, Zhiping and Huang, Fawei and Zhang, Yongsheng and Cui, Feng and Jin, Pengfei},
  title = {Zonal‐Specific Risk Stratification Integrating Magnetic Resonance Imaging and Prostate‐Specific Antigen Density for Optimizing Prostate Biopsy Selection in Prostate‐Specific Antigen 4–20 ng/mL Patients},
  journal = {The Prostate},
  year = {2026},
  doi = {10.1002/pros.70075}
}
Kostenlos starten →